Compare PRG & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | HROW |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | PRG | HROW |
|---|---|---|
| Price | $29.76 | $53.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $37.50 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 605.8K | 550.3K |
| Earning Date | 02-18-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | $250,042,000.00 |
| Revenue This Year | $1.24 | $38.96 |
| Revenue Next Year | $7.02 | $43.38 |
| P/E Ratio | $7.42 | ★ N/A |
| Revenue Growth | 3.71 | ★ 47.83 |
| 52 Week Low | $23.50 | $20.85 |
| 52 Week High | $44.43 | $51.53 |
| Indicator | PRG | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 70.16 |
| Support Level | $30.10 | $46.58 |
| Resistance Level | $30.76 | $51.53 |
| Average True Range (ATR) | 0.73 | 2.27 |
| MACD | -0.11 | 0.21 |
| Stochastic Oscillator | 33.56 | 97.18 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.